All Stories

  1. Distinct functions for the membrane proximal ectodomain region (MPER) of HIV-1 gp41 in cell-free and cell-cell viral transmission and cell-cell fusion
  2. Antibody Responses to a Quadrivalent Hepatitis C Viral-Like Particle Vaccine Adjuvanted with Toll-Like Receptor 2 Agonists
  3. Escape of Hepatitis C Virus from Epitope I Neutralization Increases Sensitivity of Other Neutralization Epitopes
  4. The antigen-binding fragment of MAb24 in complex with a peptide from Hepatitis C Virus E2 epitope I (412-423)
  5. A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81
  6. Generating broadly neutralizing antibody responses against hepatitis C using a vaccine candidate
  7. An Optimized Hepatitis C Virus E2 Glycoprotein Core Adopts a Functional Homodimer That Efficiently Blocks Virus Entry
  8. The global threat of Zika virus to pregnancy: epidemiology, clinical perspectives, mechanisms, and impact
  9. Calsyntenin-1 mediates hepatitis C virus replication
  10. The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?
  11. Monoclonal Antibodies Directed toward the Hepatitis C Virus Glycoprotein E2 Detect Antigenic Differences Modulated by the N-Terminal Hypervariable Region 1 (HVR1), HVR2, and Intergenotypic Variable Region
  12. The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
  13. Longitudinal Sequence and Functional Evolution within Glycoprotein E2 in Hepatitis C Virus Genotype 3a Infection
  14. Antibodies to the high‐density lipoprotein receptor SR‐B1 potently inhibit hepatitis C virus replication in vivo : New avenues for preventing reinfection of the liver following transplantation
  15. Challenges to the development of vaccines to hepatitis C virus that elicit neutralizing antibodies
  16. A Summary of the 20th International Symposium on Hepatitis C Virus and Related Viruses
  17. Detection of HCV-Specific IFN-γ Responses in HCV Antibody and HCV RNA Negative Injecting Drug Users
  18. High Rates of Hepatitis C Virus Reinfection and Spontaneous Clearance of Reinfection in People Who Inject Drugs: A Prospective Cohort Study
  19. Allosteric Modulation of the HIV-1 gp120-gp41 Association Site by Adjacent gp120 Variable Region 1 (V1) N-Glycans Linked to Neutralization Sensitivity
  20. Forced virus evolution reveals functional crosstalk between the disulfide bonded region and membrane proximal ectodomain region of HIV-1 gp41
  21. Identification of specific regions in hepatitis C virus core, NS2 and NS5A that genetically interact with p7 and co-ordinate infectious virus production
  22. In silico directed mutagenesis identifies the CD 81/claudin‐1 hepatitis C virus receptor interface
  23. Distinct roles in folding, CD81 receptor binding and viral entry for conserved histidine residues of hepatitis C virus glycoprotein E1 and E2
  24. Role for the Terminal Clasp of HIV-1 gp41 Glycoprotein in the Initiation of Membrane Fusion
  25. Hepatitis C Virus (HCV) Envelope Glycoproteins E1 and E2 Contain Reduced Cysteine Residues Essential for Virus Entry
  26. The SR-BI Partner PDZK1 Facilitates Hepatitis C Virus Entry
  27. Claudin Association with CD81 Defines Hepatitis C Virus Entry
  28. Role for the disulfide-bonded region of human immunodeficiency virus type 1 gp41 in receptor-triggered activation of membrane fusion function
  29. Delivery of a foreign epitope by sharing amino acid residues with the carrier matrix
  30. T CD8 response in diverse outcomes of recurrent exposure to hepatitis C virus
  31. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users
  32. An N-terminal glycine-rich sequence contributes to retrovirus trimer of hairpins stability
  33. Neutralizing antibodies in patients with chronic hepatitis C infection treated with (Peg)-interferon/ribavirin
  34. Recent Advances in Our Understanding of Receptor Binding, Viral Fusion and Cell Entry of Hepatitis C Virus: New Targets for the Design of Antiviral Agents
  35. Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain That Retains CD81 Binding
  36. Functional Links between the Fusion Peptide-proximal Polar Segment and Membrane-proximal Region of Human Immunodeficiency Virus gp41 in Distinct Phases of Membrane Fusion
  37. Induction of neutralizing antibody responses to hepatitis C virus with synthetic peptide constructs incorporating both antibody and T‐helper epitopes
  38. A self-adjuvanting multiepitope immunogen that induces a broadly cross-reactive antibody to hepatitis C virus
  39. Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2
  40. Hepatitis C Virus Glycoprotein E2 Contains a Membrane-proximal Heptad Repeat Sequence That Is Essential for E1E2 Glycoprotein Heterodimerization and Viral Entry
  41. Expression and biochemical analysis of the entire HIV-2 gp41 ectodomain: determinants of stability map to N- and C-terminal sequences outside the 6-helix bundle core
  42. Functional Evolution of the HIV-1 Envelope Glycoprotein 120 Association Site of Glycoprotein 41
  43. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins
  44. Identification of the Hepatitis C Virus E2 Glycoprotein Binding Site on the Large Extracellular Loop of CD81
  45. Equine rhinitis A virus: structural proteins and immune response
  46. Glycosylation of a Synthetic Peptide Representing a T-Cell Determinant of Influenza Virus Hemagglutinin Results in Loss of Recognition by CD4+ T-Cell Clones
  47. Conserved Determinants for CD4+ T Cells within the Light Chain of the H3 Hemagglutinin Molecule of Influenza Virus
  48. Modulation of CD4+ T-Cell Recognition of Influenza Hemagglutinin by Carbohydrate Side Chains Located Outside a T-Cell Determinant
  49. A study of the advantages and limitations of immunoblotting procedures for the detection of antibodies against influenza virus